Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

HOWL Werewolf Therapeutics Inc

Price (delayed)

$1.31

Market cap

$58.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.64

Enterprise value

$3.76M

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its ...

Highlights
Werewolf Therapeutics's debt has decreased by 28% YoY
The quick ratio has increased by 20% year-on-year and by 8% since the previous quarter
Werewolf Therapeutics's revenue has plunged by 93% YoY and by 39% from the previous quarter
The gross profit has plunged by 93% YoY and by 39% from the previous quarter

Key stats

What are the main financial stats of HOWL
Market
Shares outstanding
44.87M
Market cap
$58.78M
Enterprise value
$3.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.02
Price to sales (P/S)
51.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.29
Earnings
Revenue
$1.14M
Gross profit
$1.14M
Operating income
-$74.42M
Net income
-$72.41M
EBIT
-$67.5M
EBITDA
-$65.02M
Free cash flow
-$59.98M
Per share
EPS
-$1.64
EPS diluted
-$1.65
Free cash flow per share
-$1.34
Book value per share
$1.28
Revenue per share
$0.03
TBVPS
$2.39
Balance sheet
Total assets
$107.24M
Total liabilities
$49.93M
Debt
$37.01M
Equity
$57.31M
Working capital
$82.79M
Liquidity
Debt to equity
0.65
Current ratio
8.09
Quick ratio
7.89
Net debt/EBITDA
0.85
Margins
EBITDA margin
-5,688.5%
Gross margin
100%
Net margin
-6,335.2%
Operating margin
-6,511.2%
Efficiency
Return on assets
-54.9%
Return on equity
-89.4%
Return on invested capital
-165.1%
Return on capital employed
-70.6%
Return on sales
-5,905.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HOWL stock price

How has the Werewolf Therapeutics stock price performed over time
Intraday
-3.68%
1 week
7.38%
1 month
44.8%
1 year
-64.01%
YTD
-11.49%
QTD
34.75%

Financial performance

How have Werewolf Therapeutics's revenue and profit performed over time
Revenue
$1.14M
Gross profit
$1.14M
Operating income
-$74.42M
Net income
-$72.41M
Gross margin
100%
Net margin
-6,335.2%
Werewolf Therapeutics's revenue has plunged by 93% YoY and by 39% from the previous quarter
The gross profit has plunged by 93% YoY and by 39% from the previous quarter
The company's net income has shrunk by 74% YoY and by 2.7% QoQ
Werewolf Therapeutics's net margin has shrunk by 69% QoQ

Price vs fundamentals

How does HOWL's price correlate with its fundamentals

Growth

What is Werewolf Therapeutics's growth rate over time

Valuation

What is Werewolf Therapeutics stock price valuation
P/E
N/A
P/B
1.02
P/S
51.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.29
HOWL's EPS has plunged by 50% YoY
The equity has plunged by 51% YoY and by 22% from the previous quarter
HOWL's price to book (P/B) is 22% lower than its 5-year quarterly average of 1.3 but 13% higher than its last 4 quarters average of 0.9
Werewolf Therapeutics's revenue has plunged by 93% YoY and by 39% from the previous quarter
HOWL's price to sales (P/S) is 85% higher than its last 4 quarters average of 27.7

Efficiency

How efficient is Werewolf Therapeutics business performance
Werewolf Therapeutics's return on equity has shrunk by 147% YoY and by 22% QoQ
Werewolf Therapeutics's return on assets has shrunk by 136% YoY and by 17% QoQ
HOWL's ROS has plunged by 69% from the previous quarter
HOWL's ROIC is down by 20% QoQ

Dividends

What is HOWL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HOWL.

Financial health

How did Werewolf Therapeutics financials performed over time
The total assets is 115% higher than the total liabilities
The total assets is down by 40% YoY and by 16% QoQ
HOWL's current ratio is up by 21% year-on-year and by 9% since the previous quarter
Werewolf Therapeutics's debt is 35% lower than its equity
The equity has plunged by 51% YoY and by 22% from the previous quarter
HOWL's debt to equity is up by 48% YoY and by 27% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.